文献速递生殖医学

多囊卵巢综合征女性中无促性腺激素体外成熟与促排卵体外受精的非劣效随机对照试验

In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial.
PubMed 文献 · Hum Reprod · 2022-01-01

该单中心、开放标签、非劣效随机对照试验纳入351例多囊卵巢综合征(PCOS)不孕女性,比较一个周期无刺激体外成熟(IVM)与标准体外受精(IVF)的6个月内持续妊娠率。IVM组持续妊娠率22.3%低于IVF组50.6%,率差-28.3%(95%CI:-37.9%至-18.7%),未达非劣效。IVM组无中重度卵巢过度刺激综合征(OHSS),IVF组有10例(5.7%)中度OHSS和1例(0.6%)重度OHSS。

要点

  • 无刺激IVM一个周期的6个月内持续妊娠率低于标准IVF一个周期。
  • IVM组未发生中重度OHSS,IVF组中度OHSS 10例(5.7%)、重度1例(0.6%)。
  • 两组产科和围产期并发症发生率无统计学显著差异。

核心结论

  • 在PCOS女性中,一个周期无刺激IVM的6个月内持续妊娠率劣于一个周期标准IVF。

研究设计与样本

  • 单中心、开放标签、随机对照非劣效试验,在中国学术型不孕中心于2018年3月至2019年7月实施。
  • 共351例20-38岁PCOS不孕女性随机分配至无刺激IVM组(n=175)或标准IVF组(n=176),后者采用灵活GnRH拮抗剂方案及hCG触发排卵。
  • 两组均采用全胚冷冻和单囊胚移植策略,主要结局为随机化后6个月内持续妊娠(导致活产),非劣效界值为15%。

主要发现

  • IVM组随机化后6个月内持续妊娠(导致活产)率为22.3%,标准IVF组为50.6%,率差-28.3%(95%CI:-37.9%至-18.7%)。
  • IVM组未发生中重度OHSS;IVF组中度OHSS 10例(5.7%),重度OHSS 1例(0.6%)。
  • 两组产科和围产期并发症发生率无统计学显著差异。

临床怎么用

  • 作者认为,尽管IVM被视为PCOS女性便捷、廉价且安全的IVF替代方案,但一个周期无刺激IVM的累积活产率劣于一个周期标准IVF。
  • 作者指出,无卵巢刺激IVM的劣势可能主要源于胚胎发育潜能的限制。
  • 作者建议,进一步IVM发展应在全胚冷冻和囊胚移植设置中测试和验证。
  • 作者建议,需进一步随机对照试验评估其他IVM方案或多个IVM周期与IVF相比的有效性和安全性。

局限性

  • 该试验在单中心采用无额外刺激的IVM方案,可能限制其普适性。
  • 此外,PCOS女性IVF刺激采用GnRH激动剂触发而非hCG,可能更符合当前临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does in vitro maturation (IVM) result in non-inferior cumulative live birth rates compared to those after standard in vitro fertilization (IVF) in infertile women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: One cycle of IVM, without any stimulation, was inferior to one cycle of standard IVF in women with PCOS in terms of 6-month cumulative live birth rates, when choosing single vitrified-warmed blastocyst transfer. WHAT IS KNOWN ALREADY: IVM is an emerging alternative treatment for women with PCOS who need assisted reproductive technology. Since a minimal or even zero dose of gonadotropins are required in the IVM procedure, the occurrence of ovarian hyperstimulation syndrome (OHSS) is eliminated. Only one clinical trial comparing the pregnancy outcome between IVM with FSH priming and IVF has been reported. However, it is still unknown whether IVM treatment without any stimulation can offer a similar live birth outcome in women with PCOS as compared to that in women receiving the standard IVF procedure with ovarian stimulation. STUDY DESIGN, SIZE, DURATION: This single-centre, open-label randomized controlled non-inferiority trial in an academic infertility centre in China was performed between March 2018 and July 2019. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women aged 20-38 years with PCOS and infertility scheduled for their first IVF attempt were eligible. In total, 351 women were randomly allocated to receive one cycle of unstimulated IVM (n = 175) or one cycle of standard IVF with a flexible GnRH antagonist protocol and hCG as ovulatory trigger (n = 176). A freeze-all and single blastocyst transfer strategy was used in both groups. The primary outcome was ongoing pregnancy (leading to live birth) within 6 months after randomization. A non-inferiority margin of 15% was considered. MAIN RESULTS AND THE ROLE OF CHANCE: The IVM procedure without additional gonadotropin resulted in a lower ongoing pregnancy (leading to live birth) within 6 months after randomization compared to standard IVF treatment (22.3% vs. 50.6%; rate difference -28.3%; 95% confidence interval [CI]: -37.9% to -18.7%). Moderate-severe OHSS did not occur in the IVM group, while in the IVF group, ten women (5.7%) had moderate OHSS and one woman (0.6%) had severe OHSS. There was no statistically significant difference in the occurrence of obstetric and perinatal complications. LIMITATIONS, REASONS FOR CAUTION: The trial was conducted using an IVM protocol without additional stimulation in a single centre, which may limit its generalizability. In addition, a GnRH agonist trigger rather than hCG for IVF stimulation in women with PCOS would be more consistent with current clinical practice. WIDER IMPLICATIONS OF THE FINDINGS: Although IVM is considered to be a convenient, inexpensive and safe alternative to IVF for women with PCOS, our results indicated that one cycle of IVM without any stimulation was inferior to one cycle of standard IVF in terms of the cumulative live birth rate. The inferiority of IVM without ovarian stimulation could be mainly due to the limitations in the developmental potential of embryos. Further IVM development should be tested and validated in a freeze-only and blastocyst transfer setting. Further RCTs are needed to evaluate the effectiveness and safety of other IVM protocols or multiple cycles of IVM compared to IVF. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the National Key Research and Development Program of China (2016YFC1000201 and 2018YFC1002104) and the National Science Foundation of China (81730038). B.W.M. is supported by a NHMRC Investigator grant (GNT1176437). All other authors declare no competing interests. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov NCT03463772. TRIAL REGISTRATION DATE: 29 January 2018. DATE OF FIRST PATIENT’S ENROLMENT: 16 March 2018.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Zheng X, Guo W, Zeng L, et al. In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial. Hum Reprod. 2022. PMID: 34849920. doi:10.1093/humrep/deab243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。